Global Platinum-based Anticancer Drugs Market Research Report 2024-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2030

Global Platinum-based Anticancer Drugs Market Research Report 2024-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2030

Since the first FDA-approved platinum anticancer drug, cisplatin was launched in 1978, platinum anticancer drugs have achieved great success. Platinum drugs approved for marketing worldwide include cisplatin, carboplatin, oxaliplatin, nedaplatin, lobaplatin, and nedaplatin, and these drugs are usually used in combination with other anticancer drugs. Platinum drugs are currently applicable to bladder cancer, testicular cancer, ovarian cancer, non-small cell lung cancer, small cell lung cancer, colorectal cancer, and melanoma. Platinum-based drugs have shown significant therapeutic efficacy, but toxic side effects, susceptibility to drug resistance, and limited activity against many human cancers often hamper the widespread availability and effectiveness of these drugs.

Market Overview:

The latest research study on the global Platinum-based Anticancer Drugs market finds that the global Platinum-based Anticancer Drugs market reached a value of USD 1182.43 million in 2023. It’s expected that the market will achieve USD 1669.81 million by 2029, exhibiting a CAGR of 5.92% during the forecast period.

Advantages of platinum-based anticancer drugs

Chemotherapy, one of the most common cancer treatments, involves taking drugs designed to destroy cancer cells. Many different types of chemotherapy drugs are used to treat cancer, and one of the most commonly used classes is called platinum-based chemotherapy drugs. Platinum anticancer drugs such as cisplatin, carboplatin, and oxaliplatin have obvious therapeutic effects and clear mechanisms of action and are widely used in clinical practice. Platinum anticancer drugs are currently applicable to bladder cancer, testicular cancer, ovarian cancer, non-small cell lung cancer, small cell lung cancer, colorectal cancer, and melanoma. Platinum compounds trigger cellular responses by binding to nuclear DNA to form a variety of structural adducts, thereby inducing tumor cell apoptosis. Cisplatin is particularly effective in treating testicular cancer, increasing the long-term survival rate of testicular cancer patients from less than 10% to more than 90%. These drugs are often used in combination with other cancer drugs. For example, colorectal cancer is often treated with the FOLFOX regimen. This regimen is a combination of oxaliplatin and two other drugs called fluorouracil and folinic acid. Tumors can be shrunk sufficiently with chemotherapy, radiation therapy, and surgery to explore further treatments. Doctors refer to this as neoadjuvant therapy to reduce the intensity of symptoms and indications. Therefore, with increasing disease prevalence worldwide, increasing awareness about platinum-based drugs, development of medical infrastructure, and rising national disposable income, platinum-based drugs have become an integral part of cancer treatment, thereby bringing huge market earnings. Scientists are always looking for ways to improve the anti-tumor efficacy of platinum-based drugs, reduce toxicity and enhance their resistance.

The number of cancer patients is increasing

Platinum-based anticancer drugs are mainly used in the treatment of malignant tumors such as colorectal cancer, ovarian cancer, breast cancer, testicular cancer, lung cancer, bladder cancer, and head and neck tumors, and have become an indispensable first-line chemotherapy drug in clinical cancer treatment. In recent years, under the background of people's increasing health awareness and accelerating the aging process, the number of cancer patients worldwide has been increasing. According to the World Cancer Research Fund, in 2020, there were an estimated 18.1 million cancer cases worldwide. Of these, 9.3 million were males and 8.8 million were females. Breast and lung cancers are the most common cancers globally, accounting for 12.5% and 12.2% of all newly diagnosed cases in 2020, respectively. The other most common cancers are colon, rectum, and prostate cancer. Cancer is the leading cause of death worldwide and was kill nearly 10 million people in 2020. About one-third of cancer deaths are due to smoking, obesity, alcohol consumption, unhealthy diet, physical inactivity, and air pollution. About 30% of cancer cases in low- and lower-middle-income countries are caused by cancer-causing infections such as human papillomavirus (HPV) and hepatitis. Among the main treatment options, surgery and chemotherapy are the most effective techniques. The goal of surgery is to completely remove the cancer from the body. Platinum compounds have become a fulcrum for cancer therapy, especially ovarian, bladder, and testicular cancers. These compounds are known to cross-link the purine bases of DNA, interfere with DNA machinery, cause DNA damage, and gradually induce apoptosis in cancer cells. Cisplatin is the most commonly used platinum drug for cancer treatment. Carboplatin is a derivative of cisplatin used in the treatment of ovarian and lung cancer. Since there are many subdivided categories of platinum-based anticancer drugs and different indications, manufacturers currently focus on different fields, and the market structure of platinum-based anticancer drugs is relatively fragmented. Therefore, the huge scale of cancer patients has brought a broad demand space for the development of the platinum anticancer drug industry. Against the background of the increasing number of cancer patients, platinum-based anticancer drugs are the most widely used chemical anticancer drugs in clinical practice, and their market demand continues to increase, and the industry has a good development prospect.

Region Overview:

In 2022, the share of the Platinum-based Anticancer Drugs market in North America stood at 27.13%.

Company Overview:

The major players operating in the Platinum-based Anticancer Drugs market include Sanofi-Aventis, Jiangsu Hengrui Medicine, Hospira(Pfizer), Teva, Fresenius Kabi, etc. Among which, Sanofi-Aventis ranked top in terms of sales and revenue in 2023.

Sanofi-Aventis is a healthcare company, which is engaged in the discovery, development, manufacturing, and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, rare diseases, and multiple sclerosis; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals, and supplements. Sanofi's R&D efforts focus on advancing a combination drug to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. In 2004, Sanofi-Synthélabo merged with Aventis and changed its name to Sanofi-Aventis.

Segmentation Overview:

By type, Oxaliplatin segment accounted for the largest share of market in 2022.

Application Overview:

By application, the Colorectal Cancer segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Platinum-based Anticancer Drugs market covered in Chapter 3:

Jiangsu Hengrui Medicine
Lingnan Pharmacy
Qilu Pharmaceutical
Teva
Hospira(Pfizer)
Sanofi-Aventis
Dr Reddy's laboratories
Fresenius Kabi
Luoxin
Jiangsu Aosaikang Pharmaceutical
Mylan
Nanjing Pharmaceutical Factory
Taj Pharmaceuticals

In Chapter 4 and Chapter 14.2, on the basis of types, the Platinum-based Anticancer Drugs market from 2019 to 2030 is primarily split into:

Cisplatin
Carboplatin
Oxaliplatin
Nedaplatin
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Platinum-based Anticancer Drugs market from 2019 to 2030 covers:

Testicular Cancer
Osteosarcoma
Breast Cancer
Colorectal Cancer
NSCLC
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2019-2030) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)